1 2 3	A genome-wide association study in 10,000 individuals links plasma N-glycome to liver disease and anti- inflammatory proteins
4 5 6 7 8 9 10 11 12	Sodbo Sharapov ¹ , Anna Timoshchuk ¹ , Olga Zaytseva ² , Denis Maslov ¹ , Anna Soplenkova ¹ , Elizaveta E. Elgaeva ^{3,4} , Evgeny S. Tiys ³ , Massimo Mangino ^{5,6} , Clemens Wittenbecher ⁷ , Lennart Karssen ⁸ , Maria Timofeeva ^{9,10} , Arina Nostaeva ^{3,8} , Frano Vuckovic ² , Irena Trbojević-Akmačić ² , Tamara Štambuk ² , Sofya Feoktistova ³ , Nadezhda A. Potapova ¹¹ , Viktoria Voroshilova ^{3,12} , Frances Williams ⁵ , Dragan Primorac ¹³ , Jan Van Zundert ^{14,15} , Michel Georges ¹⁶ , Karsten Suhre ¹⁷ , Massimo Allegri ¹⁸ , Nishi Chaturvedi ¹⁹ , Malcolm Dunlop ⁹ , Matthias B. Schulze ^{20,21,22} , Tim Spector ⁵ , Yakov A. Tsepilov ^{3,23} , Gordan Lauc ² , Yurii S. Aulchenko ^{1,3}
13 14 15 16 17 18 19 20 21 22	 MSU Institute for Artificial Intelligence, Lomonosov Moscow State University, Moscow, Russia; Genos Glycoscience Research Laboratory, Borongajska cesta 83H, 10000 Zagreb, Croatia; Institute of Cytology and Genetics, Novosibirsk, 630090, Russia; Novosibirsk State University, Novosibirsk, 630090, Russia; Department of Twin Research and Genetic Epidemiology, School of Life Course Sciences, King's College London, St Thomas' Campus, Lambeth Palace Road, London, SE1 7EH, UK; NIHR Biomedical Research Centre at Guy's and St Thomas' Foundation Trust, London SE1 21 9RT, UK; Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Garmany:
23 24 25 27 29 30 32 33 34 35 37 38 30 41 23 44 5 67 89 01 23 31 23 33 34 56 78 39 01 42 34 44 56 47 44 56 47 44 56 47 45 45 45 45 45 45 45 45 45 45 45 45 45	 BrolyKnomics, 's-Hertogenbosch 5237 PA, Netherlands; Colon Cancer Genetics Group, Cancer Research UK Scotland Centre, Institute of Genetics & Cancer, Western General Hospital, The University of Edinburgh, Edinburgh EH4 2XU, UK; D D-IAS, Danish Institute for Advanced Study, Department of Public Health, University of Southern Denmark, , J.B. Winsløws Vej 9, DK-5000 Odense C, Denmark; I Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Moscow, Russia; Vavilov Institute of General Genetics Russian Academy of Sciences, 119991 Moscow, Russia; St. Catherine Specialty Hospital, Ulica Kneza Branimira 71E, Zagreh, Croatia; Department of Anesthesiology and Multidisciplinary Paincentre, ZOL, Genk/Lanaken, Belgium; Department of Anesthesiology and Multidisciplinary Paincentre, ZOL, Genk/Lanaken, Belgium; Department of Anesthesiology and Pain Medicine, Maastricht University Medical Centre, P. Debyelaan 25, Maastricht, 6229 HX, The Netherlands; Unit of Animal Genomics, WELBIO, GIGA-R and Faculty of Veterinary Medicine, University of Liège, (B34) 1 Avenue de l'Hôpital, Liège 4000, Belgium; Department of Physiology and Biophysics, Weill Cornell Medicine-Qatar, Education City, P.O. Box 24144 Doha, Qatar; Reentre Lemanique d'antalgie et neuromodulation – EHC - Morges - CH; MRC Unit for Lifelong Health & Ageing University College London, London, UK; Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam- Rehbruecke, 14558 Nuthetal, Germany; Institute of Nutrition Science, University of Potsdam, Potsdam, Germany; Wellcome Sanger Institute, Cambridge, CB10 IRQ, the UK Correspondence should be addressed to:
48	Dr. Yurii S. Aulchenko
49	yurii@bionet.nsc.ru
50	Current address:
51	GSK Medicines Research Centre
52 53	Gunnels Wood Road, Stevenage, SG1 2NY, UK

54 More than a half of plasma proteins are N-glycosylated. Most of them are 55 synthesized, glycosylated, and secreted to the bloodstream by liver and lymphoid tissues. While associations with N-glycosylation are implicated in the rising 56 57 number of liver, cardiometabolic, and immune diseases, little is known about 58 genetic regulation of this process. Here, we performed the largest genome-wide 59 association study of N-glycosylation of blood plasma proteome in 10,000 individuals. We doubled the number of genetic loci known to be associated with 60 blood N-glycosylation by identifying 16 novel loci and prioritizing 13 novel genes 61 62 contributing to N-glycosylation. Among these were GCKR. TRIB1. HP. SERPINA1 and CFH genes. These genes are predominantly expressed in the liver and show 63 64 previously unknown genetic link between plasma protein N-glycosylation, 65 metabolic and liver diseases, and inflammatory response. By integrating 66 glycomics, proteomics, transcriptomics, and genomics, we provide a resource that facilitates deeper exploration of disease pathogenesis and supports 67 68 discovery of glycan-based biomarkers.

- 69
- 70

71 During maturation, more than half of human proteins are modified by the covalent linking of complex carbohydrates – glycans¹. Glycoproteins comprise various secreted 72 73 and membrane enzymes, receptors, hormones, cytokines, immunoglobulins, as well as structural and adhesion molecules². Glycans affect the physical and chemical properties 74 of proteins and their biological function³⁻⁶. Adequate glycosylation is required for the 75 76 normal physiological action of glycoproteins, while aberrant glycosylation is increasingly implicated in human diseases⁷⁻⁹. Glycans are considered to be potential therapeutic 77 targets^{10–12}, essential part of therapeutics^{13–15}, as well as biomarkers^{16–18}, which makes 78 alvcobiology a promising field for future clinical applications. 79

N-glycosylation is the most abundant type of glycosylation¹ and, unlike other 80 types, is specific to a consensus asparagine-containing sequence (Asn-X-Ser/Thr, 81 82 where X is any amino acid except Pro) in the protein's primary structure. Human N-83 glycans are irregular branched polymers consisting of mannose, galactose, fucose, 84 sialic acid, and N-acetylglucosamine (GlcNAc) residuals, whose combinations introduce 85 a great diversity of protein glycoforms. Unlike proteins, whose primary structure is encoded in the genomic DNA sequence, the occupancy of the N-glycosylation site. and 86 87 the abundance of specific N-glycan structures are not directly encoded in the human 88 genome. Protein glycosylation depends on the interplay of multiple enzymes catalyzing

glycan transfer, glycosidic linkage hydrolysis, and glycan biosynthesis. The abundance
of specific protein glycoforms can be influenced by various parameters, including the
activity of enzymes and availability of substrates, the accessibility of a glycosylation site,
protein synthesis, and degradation¹⁹. Overall, protein glycosylation is a complex
process controlled by genetic, epigenetic, and environmental factors^{20–22}.

94 While the biochemical network of human N-glycan biosynthesis is well understood²³, little is known about *in vivo* regulation of this process²⁴, including tissue-95 and protein-specific regulation. A major part of the plasma glycoproteins consists of 96 97 immunoglobulins, produced by antibody-producing B-cells, and secreted proteins produced in the liver²⁵. Therefore, the N-glycosylation of blood plasma proteins serves 98 as an indicator of liver and B-cell function. Study of plasma protein N-glycosylation 99 100 potentially provides insights into the etiology and pathophysiology of liver and B-cell-101 mediated diseases, as well as diseases where these tissues are important players, such 102 as cardiometabolic diseases and inflammatory conditions. Understanding the 103 mechanisms underlying blood plasma glycosylation and its regulation at the tissue-104 specific level is crucial for unraveling the complex interplay between protein 105 modifications, cellular functions, and disease processes.

106 In this context, genetics offers an attractive approach to studying regulation of N-107 glycosylation in vivo and sheds light on how these molecular phenotypes are linked to human disease^{25,26}. Abundance of total plasma N-glycans can be guantified through 108 various analytical methods²⁷. As for other quantitative phenotypes, the genome-wide 109 association study (GWAS) and multivariate genetic association analysis^{28,29} may be 110 111 applied to N-glycans to identify genetic loci associated with abundance and, therefore, 112 contain genes involved in the regulation of N-glycosylation. Further integration of N-113 glycome GWAS results with other layers of biological information (e.g., biological 114 pathways, protein-protein interactions, transcriptomics, proteomics, and others) allows 115 the discovery of novel candidate genes regulating this process and provides hypotheses about biological mechanisms underlying the genetic associations^{30,31}. A joint analysis of 116 GWAS results of N-glycome and disease (e.g., pleiotropy analysis³² and analysis of 117 causal relationships using Mendelian randomization³³) can shed light on how protein 118 119 glycosylation is involved in pathogenesis of human disease and suggest possible glycome-based biomarkers. Previous GWAS of total plasma N-glycome³⁴⁻³⁷ identified 120 121 15 genetic loci and suggested the role of 19 candidate genes. These studies were supplemented with GWAS of N-glycome of immunoglobulin G (IgG)^{28,38-41}and 122 transferrin (TF)⁴² glycoproteins, identifying an additional 19 loci and prioritizing 26 123

124 candidate genes²⁵. The role of three candidate genes, encoding transcriptional factors 125 *HNF1A*, *IKZF1*, and *RUNX3*, in the regulation of N-glycosylation was experimentally 126 confirmed *in vitro*^{34,40}. A Mendelian randomization study of IgG N-glycome found that 127 the abundance of N-glycans with bisecting GlcNAc is a potential biomarker of systemic 128 lupus erythematosus⁴³. However, there remains a limited understanding of the role of 129 genes-regulators of N-glycosylation in health and disease.

130 The first aim of this study was to identify novel glycome quantitative trait loci 131 (glyQTLs), prioritize novel candidate genes, and reconstruct tissue-specific gene 132 networks that regulate plasma protein glycosylation. For this, we performed the largest genome-wide association meta-analysis (GWAMA) of total plasma N-glycome using 133 134 data from seven studies (N = 10,764). For replicated glyQTLs, we prioritized candidate 135 genes using a broad spectrum of methods and explored how these genes are 136 connected in a functional tissue-specific network that regulates protein glycosylation. 137 The second aim of this study was to identify potential glycan biomarkers for disease. 138 We performed a phenome-wide association study (PheWAS) in conjunction with 139 colocalization analysis to investigate the pleiotropic effects of glyQTLs on complex 140 diseases. Next, we correlated genetically predicted glycan levels in 450,000 UK 141 Biobank samples with the disease's endpoints. Finally, we conducted a bidirectional 142 Mendelian randomization study to identify potential causal effects between glycans and 143 disease. This strategy not only resulted in the discovery of new candidate genes but 144 also suggested how some of these genes might regulate glycosylation enzymes and 145 how they are linked to the aberrant glycosylation observed in disease.

146 Results

147 Single- and multi-trait GWASs for 138 N-glycome traits

148 The levels of 36 N-glycan structures (Supplementary Table 3a, 3c) linked to various 149 plasma glycoproteins were measured by ultra-high performance liquid chromatography 150 in seven participating cohorts from six countries. Majority of 10,764 participants (94.5%) 151 were of European ancestry. From the 36 directly measured N-glycans, we computed 81 152 derived N-glycome traits such as the total level of fucosylation, galactosylation, 153 sialylation and others, reflecting pathways of N-glycan biosynthesis (Supplementary 154 Table 3a). We conducted GWAS for each of these 117 N-glycome traits in each of the 155 seven participating cohorts, assuming an additive model of the genetic effect. We then 156 performed a fixed-effect discovery meta-analysis of the subcohorts that included

participants of European descent (N = 7,540) (Supplementary Table 1b). After metaanalysis, we took advantage of the correlation structure between 117 N-glycome traits and performed GWAS of 21 multivariate N-glycome traits defined based on their biochemical similarities (Supplementary Table 1b).

161 The size of the replication sample (N = 3,224, Supplementary Table 1b) was 162 defined as to achieve 80% statistical power for a replication of the true association 163 signal (Supplementary Note).

The genomic control inflation factor in the discovery GWAMA varied from 1.004 to 1.059. By contrast, an intercept of LD score regression⁴⁴ varied from 0.996 to 1.002 (Supplementary Table 4c), confirming minimal impact of genetic stratification on the GWAS results. Hence, implementing Genomic Control correction in the analysis was unnecessary.

169 Our analyses identified and replicated a total of 40 loci (**Fig. 1a**, Supplementary 170 Table 5a, Supplementary Table 5b) that were significantly associated with at least one 171 of 117 N-glycome traits and 21 multivariate N-glycome traits. The association of 25 loci 172 with total plasma N-glycome was shown and replicated for the first time (**Table 1**), while 173 the association of 15 loci confirms previous findings^{36,37}.

174 We performed an approximate conditional and joint analysis implemented in GCTA-COJO⁴⁵ to identify conditionally independent association signals in the replicated 175 176 loci on discovery GWAMA. We found evidence of multiple SNPs contributing 177 independently to glycan level variation for nine loci (Supplementary Table 6a). Seven of 178 these loci span glycosyltransferase genes, coding for enzymes directly involved in the 179 biosynthesis of glycans. Two sentinel associations were observed in the loci containing fucosyltransferases FUT8 and FUT6, sialyltransferases ST6GAL1 and ST3GAL4, 180 181 galactosyltransferase B4GALT1, glycuronyltranferase B3GAT1, and the 182 acetylglucosaminyltransferase MGAT5. Beyond glycosyltransferase loci, the locus 183 spanning the human leukocyte antigen (HLA) and the locus containing HPR gene 184 showed secondary associations.

185 SNP-based heritability and whole genome polygenic scores for 117 N-glycome traits

For 117 N-glycome traits we estimated SNP-based heritability using LD Score regression⁴⁴. For 68 N-glycome traits SNP-based heritability was above zero at nominal $P \le 0.05$, varying from 10.2% to 33.4% (19.8 ± 10.3%) (Supplementary Table 4c), which is on average 2.5x lower than the narrow-sense heritability of 37 N-glycome traits, estimated in a twins-based study – 50.6 ± 14.0%⁴⁶.

191 For each of the 117 N-glycome traits, we created polygenic score (PGS) models 192 based on the GWAMA of European-ancestry participants (N = 10,172) using the SBayesR method⁴⁷. We tested the out-of-sample prediction accuracy of these models in 193 194 the CEDAR dataset (N=187 participants of European ancestry). For 79 N-glycome traits in CEDAR samples, PGS models explained from 2.4% to 20.0% of the trait variance 195 196 (FDR < 5%), allowing for calculation of genetically predicted glycan levels in large scale 197 cohorts of European descent (e.g., UKBiobank). For the remaining 38 N-glycome traits 198 the explained variance did not deviate significantly from zero (FDR > 5%). The out-of-199 sample prediction accuracy correlated significantly with the SNP-based heritability 200 $(R = 0.48, P = 4.05 \times 10^{-8})$. The implementation of SBayesR models is detailed in 201 Supplementary Table 7.

202 Prioritization of causal genes for protein N-glycosylation

203 Identification of genes, rather than genetic loci, can help to find novel protein 204 glycosylation regulators and suggest targets for intervention in glycome-related 205 diseases. To prioritize the most likely effector genes, we employed a consensus-based 206 prioritization approach selecting the gene with the highest unweighted sum of evidence 207 from eight different predictors - based on a literature search of genes encoding known 208 enzymes and regulators of N-glycan biosynthesis; genes causing congenital disorders 209 of glycosylation; colocalization of glyQTLs with eQTLs and blood plasma pQTLs; 210 annotation of putative causal variants affecting protein structure; enrichment of gene 211 sets and tissue-specific expression; and prioritization of the nearest gene (see 212 Methods). We prioritized the most likely effector gene for each locus by selecting the 213 gene with the highest unweighted sum of evidence across all eight predictors⁴⁸, 214 provided a gene was supported by at least two predictors.

We prioritized candidate genes in 31 of the 40 glyQTLs (Supplementary Table 6b). The prioritized genes may regulate the protein N-glycosylation through several known general mechanisms: biosynthesis of N-glycans, abundance of N-glycoproteins in the blood, regulation of transcription in lymphoid and gastrointestinal tissues, and ion homeostasis in the endoplasmic reticulum and Golgi apparatus.

Among the 31 prioritized genes (**Fig. 2b**), we identified nine genes encoding glycosyltransferases (*MGAT5, ST6GAL1, B4GALT1, ABO, ST3GAL4, B3GAT1, FUT8, FUT6, MGAT3*); mutations in three are known to lead to congenital disorders of glycosylation (*B4GALT1, FUT8, SLC39A8*) and four genes have strong experimental support for being regulators of N-glycan biosynthesis genes (*HNF1A, IKZF1, RUNX3,*

225 SLC39A8)²⁵. The SMR/HEIDI approach indicated that total plasma N-glycosylation-226 associated variants in two loci possibly had pleiotropic effects on plasma levels of two 227 blood proteins (HPT, CAFH) (Supplementary Table 6g) and transcription of 10 genes in 228 different tissues (Supplementary Table 6f). In 12 genes, associated variants were either 229 coding or were in strong LD with the variants coding for potentially deleterious amino acid changes (annotated by Variant Effect Predictor, VEP49), and in 5 genes -230 pathogenic amino acid changes (predicted by FATHMM XF⁵⁰ and FATHMM InDel⁵¹). 231 The DEPICT gene prioritization tool³¹ provided evidence of prioritization for 19 genes in 232 233 18 loci at FDR < 0.2 (Supplementary Table 6h).

Because not all the glyQTLs were colocalized with a cis-eQTL, cis-pQTL or lay in proximity to biologically relevant genes, we also utilized the nearest protein-coding genes as an independent predictor. This approach was chosen due to the tendency of the nearest protein-coding genes to enrich for molecular QTLs⁵².

238 In the following discussion, we focus on thirteen novel candidate genes that were 239 not identified before in GWASs of human protein N-glycosylation; for the latter, we refer 240 a reader to previous works and published reviews²⁵. We prioritized four genes 241 associated with lipid metabolism regulation - GCKR, FADS2, TRIB1, and GRAMD1B 242 which, to our knowledge, is the first time protein N-glycosylation has been linked to 243 genes involved in lipid metabolism and its regulation; four genes encoding N-244 glycoproteins having anti-inflammatory function - HP, HRP, SERPINA1 and CFH; the 245 gene SCL39A8 encoding a zinc transporter; three genes encoding transcription factors -246 MAX, NFKB1, MYRF; and a glycosyltransferase gene ABO, which determines an 247 individual's ABO blood type.

The Supplementary Note provides an in-depth account of the details of thirteen newly prioritized genes. The other genes that have been previously prioritized elsewhere are described in Timoshchuk et al.²⁵.

251 Tissue-specific regulation of plasma protein N-glycosylation

Lymphoid tissue, specifically plasma cells that produce antibodies, and liver, specifically hepatocytes, contribute the majority of glycoproteins present in human blood^{2,25} and are thus the primary drivers of N-glycosylation of plasma proteome. However, the N-glycosylation machinery in these two cell types varies, leading to distinct spectra of glycans attached to proteins produced in these two tissues^{2,46}. Many glycosylation-associated genes prioritized in this study are expressed in plasma cells, or hepatocytes, or both (**Fig. 2a**).

259 To gain a deeper understanding of the tissue-specific regulation of glyco-genes, 260 we constructed a gene network for N-glycosylation regulation. This network comprised 261 32 loci that were replicated in the univariate association analysis, and 117 N-glycome 262 traits as vertexes, with significant associations between them represented as edges 263 (Fig. 1b). The resulting network revealed two major subnetworks, wherein candidate 264 genes and glycan traits were clustered. The first subnetwork was primarily associated 265 with blood plasma N-glycans typically produced in the liver, and included 13 loci 266 (ATF6B, B3GAT1, CHST2, FUT6, HNF1A, HP, LINC02714, MAX, MGAT5, MLXIPL, 267 SERPINA1, ST3GAL4, TRIB1). The second subnetwork was related to blood plasma N-268 glycans typically attached to immunoglobulins and consisted of 14 loci (B4GALT1, 269 ELL2, HIVEP2, IKZF1, MEF2B, MGAT3, RUNX1, SLC38A10, SLC39A8, SMARCB1, 270 SMARCD3, TNFRSF13B, TMEM121, TXLNB). According to classification of Clerc et 271 al.², genetic variation in five loci (containing FUT8, GCKR, GRAMD1B, RUNX3, and 272 ST6GAL1) had an impact on plasma N-glycans attached to both immunoglobulins and 273 liver-secreted proteins. Most of these five loci exhibited strong bias towards N-glycans 274 known to be preferentially expressed on proteins produced in one of the tissues, i.e., 275 GRAMD1B was associated with 8 N-glycans, of which 7 were typical for liver proteins; 276 GCKR - with 9, of which only one was typical for immunoglobulins; RUNX3 and 277 ST6GAL1 were preferentially associated with N-glycans typically attached to 278 immunoglobulins (32/35 and 43/44 glycans, respectively). It should be noted that the classification of Clerc et al.² was compiled based on a large body of literature data, and 279 280 we cannot exclude occasional misclassification.

281 To gain insight into the spectrum of glycans that were associated to the 8 loci that 282 were replicated in multivariate association analysis, we considered significant (at 283 p < 0.01/36) association of the partial regression coefficients in the multivariate analysis 284 of trait set "N-glycosylation" (36 traits) (Supplementary Table 5e). In this analysis, 285 DIPK1A, FADS2, and CALB2 loci associated with N-glycans typical for liver-secreted proteins; LOC107985440 - with N-glycans typically observed on immunoglobulins IaG. 286 287 Results for ST3GAL6 and LOC157273 were inconclusive, although the former was 288 associated with the multivariate trait "high branching N-glycans"; such glycans are 289 typical for liver-secreted proteins.

Three loci showed clear effect on N-glycans found on both liver-secreted glycoproteins and immunoglobulins: *FUT8* (significant effect on 9 N-glycans typically attached to liver-secreted proteins and 3 typically attached to immunoglobulins); *CFH* (2 and 2, respectively) and *ABO* (also 2 and 2).

294 TF and IgG are two proteins secreted by hepatocytes and plasma cells, 295 respectively, and GWASs of their N-glycosylation shed light on the genetic control of protein N-glycosylation in the corresponding tissues⁴². To gain further insights into the 296 297 mechanism of association and to support the tissue-specificity of the loci, we conducted 298 a colocalization analysis of total plasma, IgG and TF glyQTLs using the SMR-0 method⁵³. The analysis was restricted to the loci that were previously implicated in TF⁴² 299 N-glycome or IgG⁴⁰ N-glycome GWASes, and reached genome-wide significance in 300 301 univariate association analysis in this study. Excluding HLA, this selection resulted in 21 302 loci, of which 15 were significant in previous IgG N-glycome GWAS only, four were only 303 significant in the TF N-glycome GWAS, and two (FUT6 and FUT8) were significant in both (Supplementary Table 5d)²⁵. For specific locus, we colocalized signals of genetic 304 305 association for traits that have reached genome-wide significance in that locus.

306 The results of colocalization analysis are presented in Supplementary Figures 3. 307 If regional genetic associations of a plasma N-glycome trait colocalized ($|\theta| > 0.7$) with 308 genetic associations of an IgG N-glycome trait, we considered this as evidence that the 309 locus is expressing its effect on plasma N-glycome through its effect on IgG N-310 glycosylation, acting in antibody-producing cells. Similarly, colocalization with genetic 311 association signal for TF N-glycome was taken as an indication that the locus may 312 exhibit its action via effect of TF N-glycome, acting in liver. The analysis suggested that 313 the ELL2, TXLNB, HIVEP2, IKZF1, SMARCD3, TMEM121, SLC38A10, MEF2B, 314 ATF6B, RUNX1, RUNX3, SMARCB1, MGAT3, ST6GAL1, B4GALT1 loci regulate N-315 glycosylation of IgG while MGAT5, ST3GAL4, B3GAT1, HNF1A loci regulate N-316 glycosylation of TF. The FUT8 and FUT6 act as regulators of both glycoproteins. An 317 interesting case of pleiotropy was observed in the FUT8 locus. The colocalization signal 318 in FUT8 split into two distinct clusters (Supplementary Fig. 3, page 120), one of which 319 was dominated by N-glycans predominantly presented on proteins produced in the liver, 320 while the other was almost exclusively presented by these on immunoglobulins. To 321 support the hypothesis of two distinct tissue-specific genetic mechanisms in the locus, we combined traits from the two clusters into single traits using MANOVA approach²⁸ 322 323 and performed a colocalization analysis between the two constructed linear combinations using the SMR- θ method⁵³ and R Coloc package⁵⁴. We found strong 324 325 evidence against colocalization of N-glycans presented on liver-specific proteins and 326 these on immunoglobulins in this genomic region (PP.H3 = 100%, where PP.H3 is the 327 posterior probability that there are two distinct causal variants contributing to trait variation, $\theta = 4 \times 10^{-6}$). This supports the hypothesis that genetic regulation of *FUT8* in 328

the liver and antibody-producing cells follows two distinct mechanisms, as previously
 suggested by Landini and colleagues⁴².

Thus, the colocalization analysis confirms different tissue-specific mechanisms of genetic regulation for each locus. With an exception of the *ATF6B* and *FUT6* loci, the results from colocalization are largely consistent with the classification based on gene-N-glycan association network.

Our findings demonstrate that the genetic regulation of protein N-glycosylation is highly tissue-specific. Even glycosyltransferases such as *FUT8*, *FUT6*, *MGAT3*, *ST6GAL1* and *B4GALT1*, being expressed in antibody-producing cells and hepatocytes (Fig. 2a) and known to participate in the N-glycan biosynthesis in both tissues, display pronounced tissue-specific genetic regulation that is not shared between different tissues.

341 PheWAS highlights loci associated with an extensive number of diseases and342 quantitative traits

343 In this study, we examined the pleiotropic effects of 40 replicated glyQTLs on over a 344 thousand diseases and quantitative traits endpoints (as listed in Supplementary Table 345 8a) using the SMR/HEIDI method. Our analysis revealed a total of 1,214 significant 346 associations, of which 781 demonstrated a non-rejection of the pleiotropy hypothesis by 347 the HEIDI test. The identified pleiotropic associations encompassed a wide range of 348 phenotypes, including type 2 and type 1 diabetes, blood glucose levels, coronary artery 349 disease, cholesterol levels, bipolar disorder, schizophrenia, gout, various oncological 350 diseases, metabolomic and anthropometric traits, lifestyle and diet-related traits, general 351 life history and overall health status, among others (as depicted in Fig. 3a, 3b and 352 Supplementary Table 8b). Additionally, TRIB1 and GCKR showed colocalization with metabolic dysfunction-associated steatotic liver disease (*TRIB1*: $P_{SMR} = 4.58 \times$ 353 354 10^{-8} , $P_{HEIDI} = 0.03$ (possibly shared); GCKR: $P_{SMR} = 3.26 \times 10^{-8}$, $P_{HEIDI} = 0.73$ (likely 355 shared)).

Hierarchical clustering based on sets of colocalized traits allowed us to differentiate four distinct groups of loci (**Fig. 3a**, right panel). The first cluster (**Fig. 3a**, topmost cluster) was characterized by a high number of metabolic colocalizations and encompassed eight of the ten most pleiotropic loci (**Fig. 3c**). It was also found to be colocalized with a diverse range of other phenotypes, including disease and anthropometric traits. Of particular note, this cluster comprised loci with prioritized lipid metabolism genes, namely, *GCKR*, *TRIB1*, *FADS2* and previously known *HNF1A*.

Furthermore, it encompassed the locus containing the *MLXIPL* gene, a transcriptional factor that induces liver glycolysis and lipogenesis, as well as *ABO*, which is known to be associated with stroke⁵⁵, metabolic dysfunction-associated steatotic liver disease and levels of lipids^{56,57}.

367 Association between PGS for plasma N-glycosylation traits and ICD-10 diseases

We analyzed associations between polygenic scores (PGS) for the 117 plasma 368 N-glycosylation traits and 167 diseases classified according to International 369 370 Classification of Diseases (ICD)-10 in individuals of European ancestry from the UK 371 Biobank cohort (N = 374.303) (Supplementary Note). The analysis revealed 14 372 diseases associated with PGS for at least one plasma N-glycome trait and PGS for 35 373 plasma N-glycome traits associated with at least one disease at the designated significance threshold of $p < 1.07 \times 10^{-5}$ (Fig. 4, Supplementary Table 9). Full results 374 375 and overview of the analysis are provided in the Supplementary Note.

Notably, we observed positive associations between PGS for traits, related to the increased levels of high-mannose glycans, especially to those of containing nine mannsoe residuals (M9), with cardiovascular disease phenotypes such as essential hypertension, ischemic heart disease, angina, hyperlipidaemias, as well as type 1 diabetes and asthma (**Fig. 4**).

We found negative associations for the PGS for S0 total (percentage of neutral N-glycan structures, i.e. N-glycans without sialic acid, in total plasma N-glycans) with primary hypertension, lipidaemias, obesity and non-insulin dependent diabetes (**Fig. 4**). Moreover, PGS for the N-glycome traits describing the abundances of galactosylated structures were negatively associated with obesity, lipoprotein metabolism disorders, primary hypertension and type 2 diabetes (**Fig. 4**).

387 Bidirectional Mendelian Randomization analysis of causal effects between plasma N-

388 glycosylation traits and ICD-10 diseases

For the statistically significantly associated pairs of disease-plasma N-glycome
 traits in UK Biobank we conducted bidirectional two-sample Mendelian randomization
 (MR) analysis to investigate the direction of effects.

Using the disease phenotype as exposure, we conducted a two-sample MR analysis and revealed statistically significant positive causal effect of disorders of lipoprotein metabolism on M9 (N-glycan with nine mannose residuals) and on Mtotal (the percentage of high-mannose structures in total plasma glycans) (**Table 2**, Supplementary Table 10b, Supplementary Fig. 6a-d, 7a-d). The direction of the causal

effect corresponded to the signs of the beta of association between disorders of
lipoprotein metabolism and other lipidaemias (E78) and PGS for M9 and Mtotal.
Sensitivity analyses, including a two-sample MR after removal of pleiotropic IVs, as well
confirmed the observed causal effects of lipidaemias (E78) on M9 and Mtotal
(Supplementary Fig. 8a-d, 9a-d; Supplementary Tables 11a-c, 13a-c, Supplementary
Note).

403 Using plasma N-glycome trait as exposure we performed MR analysis in the 404 opposite direction, discovering a statistically significant positive causal effect of M6n, 405 percentage of M6 in total neutral plasma glycans on asthma and a positive effect of 406 M9n, percentage of M9 in total neutral plasma glycans, on disorders of lipoprotein 407 metabolism and other lipidaemias (Table 2, Supplementary Table 10a, Supplementary 408 Fig. 4a-d; 5a-c). In both cases, the direction of the effect was concordant with the 409 direction of association between corresponding pairs of disease and PGS. Sensitivity 410 analyses also confirmed the observed causal effect (Supplementary Tables 11a-c). Since the number of available IVs for both M6n and M9n was not sufficient for the 411 412 analysis of pleiotropy among the IVs using MR-PRESSO⁵⁸, as an additional sensitivity 413 analysis for the effects of M6n on asthma and M9n on lipidaemia we performed 414 colocalization (SMR-HEIDI) analysis for the loci tagged by the genetic variants used as 415 IVs in these cases (Supplementary Table 12). SMR-HEIDI analysis provided evidence 416 for one shared causal variant (rs144126567, $p_{SMR} = 0.003$; $p_{HEIDI} = 0.30$) for M6n and 417 asthma but did not find any proof for existence of shared genetic variants influencing 418 M9n and lipidaemia (Supplementary Table 12). Therefore, we report an observed 419 positive effect of M6n on asthma, while the presence of a positive effect of M9n on 420 lipidaemia remains inconclusive. Full results of MR analysis are presented in 421 Supplementary Tables 10a-b.

422 Discussion

Here, we reported 40 quantitative trait loci (glyQTLs) discovered in the GWAS of 138 blood plasma N-glycome traits, resulting in a more than two-fold expansion of loci affecting N-glycosylation of blood plasma proteins. The integration of these findings with genetic information related to human diseases and other complex phenotypes allowed us to show for the first time that genes involved in liver function are linked to the human blood plasma protein N-glycosylation.

429 A subset of newly prioritized genes allows us to postulate a link between genetic 430 regulation of metabolic and liver diseases and blood plasma protein N-glycosylation.

431 Specifically, common genetic variation in the loci near *GCKR and TRIB1* is known to 432 predispose to metabolic dysfunction-associated steatotic liver disease (MASLD)⁵⁹. 433 Moreover, genetic association signal for MASLD in these loci are colocalized with the 434 corresponding glyQTLs. In the gene *SERPINA1*, rare Mendelian mutations lead to 435 alpha-1 antitrypsin (AAT) deficiency, with liver disease as part of the phenotype. 436 Common variation in this region associates with chronic elevation of alanine 437 aminotransferase (cALT) levels⁶⁰, a proxy phenotype for MASLD.

Although on phenotypic level, the changes of total and liver secreted proteinspecific N-glycosylation in liver disease are well-known^{61–63}, we demonstrate, for the first time, that specific genes are associated with both N-glycosylation and liver disease, offering a starting point for genetically-guided investigation of the functional mechanisms of this phenotypic association.

443 Somewhat superficially, we may reason that liver disease is characterized by 444 hepatocyte injury and endoplasmic reticulum stress⁶⁴, which is strongly associated with 445 changes in glycosylation. A less direct mechanism could be inflammation, that is a 446 hallmark of liver disease, with proinflammatory cytokines shown to alter the substrate 447 synthesis pathways as well as the expression of glycosyltransferases required for the biosynthesis of N-glycans⁶⁵. Thus, changes in N-glycosylation observed in blood 448 449 plasma may be at least partly explained by altered N-glycosylation of hepatocyte-450 secreted proteins. Consistently with this hypothesis, we demonstrate that common 451 genetic variation in the three loci known to be associated with liver disease is 452 associated with variation in abundance of N-glycans, typically attached to the liver-453 secreted proteins.

454 Other notable, partly overlapping, subset of liver-expressed genes newly 455 implicated in plasma protein N-glycosylation encodes anti-inflammatory proteins --456 haptoglobin (HP, HP), complement factor H (CFAH, CFH), and alpha-1-antitrypsin 457 (AAT, SERPINA1). The glyQTLs located at HP and CFH are colocalized with the 458 corresponding pQTLs. At least two mechanisms may be suggested to explain such 459 colocalization. Genetic variants in these loci may affect the composition of blood N-460 glycosylation through changes in the abundance of glycans preferentially bond to HP 461 and CFAH by regulating the level of these glycoproteins in the blood. Alternatively, the 462 genetic variation may change glycosylation of these proteins, which, in turn, could 463 change the affinity of the binding of the specific probes used by the SomaLogic assays. 464 While we did not observe colocalization between SERPINA1 glyQTL and the AAT 465 pQTL, this may be a false negative, potentially explained by the low frequency of the

466 *SERPINA1* lead variant (rs28929474). Nonetheless, the rs28929474 is associated with 467 the level of glycoprotein acetyl, a mixture of N-glycoproteins, predominantly 468 alpha-1-acid glycoprotein, haptoglobin, and alpha-1-antitrypsin⁶⁶.

469 While variation at HP and SERPINA1 loci is associated with changes in N-470 glycans typically attached to liver proteins, CFH locus appears to also affect N-glycans 471 typically attached to immunoglobulins. While CFH does express at some level in plasma 472 cells (Fig. 2a), we speculate that perhaps a more likely mechanism is that genetic 473 variation in CFH affects its expression liver, and changes in N-glycans attached to 474 immunoglobulins occur through a systemic mechanism, i.e., regulation of inflammation. 475 Consistent with this hypothesis is the known association of the CFH locus with IgA nephropathy⁶⁷, as well as indications that in mice, that CFH modulates splenic B cell 476 477 development and limits autoantibody production⁶⁸.

478 Our results suggest that genetic regulation of plasma protein N-glycosylation 479 predominantly occurs in lymphoid and liver tissue and exhibits strong tissue specificity. 480 Integration of evidence from transcriptomics and N-glycomics suggests that molecular 481 expression of genetic variation in the majority of glyQTLs is restricted to one tissue; the 482 effects of this variation on N-glycans in blood plasma occur either through changes of 483 N-glycosylation of the proteins secreted by the tissue, or through systemic mechanisms. 484 Of note, all of N-glycosyltransferase genes that express on RNA, protein, and glycan levels in both tissues, are genetically regulated in only one of them (B4GALT1. 485 486 ST6GAL1, MGAT3), or exhibit different glyQTLs in different tissues (FUT8, FUT6). Even 487 thus, while a number of glycosyltransferases are expressed both in liver and lymphoid 488 tissues, we provide evidence that the genetic variation regulating N-glycosylation in 489 each of the two tissues is unique and does not overlap at the available resolution of the 490 analysis. To the best of our knowledge, this is the first study to analyze and reveal the 491 strong tissue-specificity of the genetic regulation of population variability of human 492 protein N-glycosylation.

493 Further studies of the genetic regulation of N-glycosylation of individual proteins 494 rather than bulk N-glycome will lead to the discovery of novel glyQTLs, which we cannot 495 observe now due to a lack of power or noise in bulk N-glycome. Quantification of the Nglycome of purified proteins like IgG⁴⁰, TF⁴², IgA^{69,70}, and apolipoprotein CIII⁷¹, and 496 497 other proteins, will be highly relevant to understanding the etiology of such disease, as 498 rheumatoid arthritis, hepatocellular carcinoma, IgA nephropathy, endocarditis¹. 499 Alternatively, development and application of computational deconvolution approaches may be similar to those applied for bulk RNA-Seq⁷². 500

In conclusion, our study offers insight into the genetic factors influencing blood plasma N-glycome, and, for the first time, establishes a genetic link between Nglycosylation, liver disease, and anti-inflammatory proteins. The identification of novel genes associated with metabolic and liver disease and N-glycosylation contributes to deeper understanding of shared biological mechanisms and will facilitate future biomarker discovery and interpretation.

507 Methods

508 We conducted a multicenter study using data from seven studies – TwinsUK (N = 509 3,918), EPIC-Potsdam (N = 2,192), PainOmics (N = 1,873), SOCCS (N = 1,742), 510 SABRE (N = 544), QMDiab (N = 325), and CEDAR (N = 170) with a total sample size N 511 = 10,764. Local research ethics committees approved all studies, and all participants 512 gave written informed consent. The detailed description of the cohorts is shown in 513 Supplementary Table 1 and Supplementary Notes.

514 Glycome measurement and phenotype processing

515 Plasma N-glycome quantification of samples from all but SOCCS studies was performed at Genos Ltd using the protocol published previously⁷³. Briefly, plasma N-516 glycans were enzymatically released from proteins by PNGase F, fluorescently labeled 517 518 with 2-aminobenzamide and cleaned-up. Fluorescently labeled and purified N-glycans 519 were separated by HILIC on a Waters BEH Glycan chromatography column. The 520 fluorescence detector was set with excitation and emission wavelengths of 250 nm and 521 428 nm, respectively. Plasma N-glycome quantification for SOCCS samples was done 522 at NIBRT by applying the same protocol with the only difference in the excitation wavelength (330 nm instead of 250 nm). Glycan peaks (GPs) - quantitative 523 524 measurements of glycan levels – were defined by manual integration of intensity peaks 525 in the chromatograms or were defined by automatic integration. The number of defined 526 GPs varied among studies from 36 to 42, therefore to conduct multi-center association 527 analysis followed by meta-analysis, we harmonized the set of GPs by applying a recently published protocol³⁴ to a harmonized set of 36 GPs. To reduce experimental 528 variation in glycan measurements, before genetic studies, raw glycan data were 529 probabilistic median quotient normalized^{74,75} and batch corrected centrally by the 530 phenotype provider (Genos Ltd). More detailed information on glycan preprocessing can 531 532 be found in the Supplementary Note. From the 36 directly measured glycan traits, 81 533 derived traits were calculated (Supplementary Table 3a). These derived traits average

534 glycosylation features such as branching, galactosylation, and sialylation, etc, across 535 different individual glycan structures and, consequently, they may be more closely 536 related to individual enzymatic activity and underlying genetic polymorphism.

537 Discovery and replication genetic association analysis

538 Single trait association analysis

539 Discovery genome-wide association studies were performed in (sub) cohorts of 540 European descent: TwinsUK (N = 2,739), EPIC-Potsdam (N = 2,192), PainOmics (N = 541 1,873), SOCCS (controls, N = 459) and SABRE (N = 277) with a combined sample size 542 of 7,540 (Supplementary Table 1b). Prior to GWAS, the total plasma N-glycome traits 543 were adjusted for sex and age, and the residuals were quantile transformed to normal 544 distribution. The genetic association analysis in each cohort was conducted using a 545 similar protocol. We assumed an additive model of genetic effects. GWAS were based on the genotypes imputed from Haplotype Reference Consortium Results⁷⁶ or 1000 546 Genomes project⁷⁷. Results of GWAS in each discovery cohort passed a strict quality 547 548 control procedure followed by fixed-effects inverse-variance weighted meta-analysis. 549 After guality control, 8.8 M SNPs were used for the downstream analysis.

To define genome-wide significant glyQTLs, we used conventional genome-wide significance threshold, Bonferroni corrected by 28 independent glycan traits ($P \le 1.79 \times 10^{-9}$) as suggested before⁷⁸. We considered SNPs located in the same locus if they were located within 250 Kb from the leading SNP (the SNP with lowest *P*). Only the SNPs and the traits with lowest *P* are reported (leading SNP-trait pairs) in the **Table 1**. The detailed procedure of locus definition is described in Supplementary Note.

556 Replication GWAS were performed using (sub) cohorts of samples with 557 European descent: SOCCS (colorectal cancer cases, N = 1,283), TwinsUK (N = 1,179), 558 CEDAR (N = 170); South Asian descent: SABRE (N = 267) and Arabian, Indian, Filipino 559 descent: QMDiab (N = 325) (Supplementary Table 1b). Results of GWAS in each 560 discovery cohort passed a strict quality control procedure followed by fixed-effects 561 inverse-variance weighted meta-analysis. For replication of novel glyQTL, found at the discovery step, we used the leading SNP-trait pair that showed the most significant 562 association. The replication threshold was set as P < 0.05/28 = 0.00178, where 28 is 563 564 the number of replicated loci. Moreover, we checked whether the sign of estimated 565 effect was concordant between discovery and replication studies.

566 Identification of secondary associations in glyQTLs

567 To identify secondary association signals at glyQTL in univariate analysis and capture the overall contribution to phenotypic variation, we performed conditional analysis using 568 GCTA-COJO software, version 1.93.2beta⁴⁵. This method uses summary-level statistics 569 570 from a discovery meta-analysis and LD corrections between SNPs estimated from a 571 reference sample for implementing a stepwise selection procedure including a series of 572 conditional and joint regression analyses in which the SNP with the strongest 573 association in the region is added to the regression model until no additional SNPs 574 reach genome-wide significance. We used 1,429 unrelated individuals with European 575 descent from SABRE cohort as reference samples for LD calculation. We used 576 $P \le 1.79 \times 10^{-9}$ as a genome-wide significance level and a default window setting to 577 identify lead associations (Supplementary Table 6a).

578 Multi-trait association analysis

579 To gain additional power of glyQTL detection, we performed a multivariate 580 GWAS of total plasma N-glycome. It has been previously demonstrated that multivariate 581 genetic association analysis of N-glycome, that is, a joint analysis of multiple N-glycome 582 traits, has higher power for loci detection than a regression model under which glycome 583 traits are analyzed independently of each other^{28,41}.

For discovery and replication analyses, we used discovery and replication 584 585 GWAMA summary statistics, obtained in single-trait analysis. The discovery multivariate 586 analysis was performed using the MANOVA-based method, adopted for analysis of a 587 group of single-trait GWAS summary statistics (details are in Supplementary Note Discovery multivariate analysis)²⁸. Discovery analysis was performed using the 588 589 MultiABEL R package. Due to method requirements, we filtered out SNPs with sample 590 size lower than 6,790 (which is 90% of 7,540 samples). The statistical significance 591 threshold for multivariate analysis was set at $P < 5 \times 10^{-8}$ /21, where 21 is the number 592 of multivariate traits described in Supplementary Table 3b and Supplementary Note. 593 GlyQTLs with significant association were defined in the same way as for single-trait 594 discovery.

595 For replication of multi-trait associated glyQTLs we used a complex four-step 596 replication strategy as proposed by Ning et al.²⁹, which consists of the following steps: 597 MANOVA, Phenotype Score, Pearson correlation method and Kendall correlation 598 method. In the first step (MANOVA) we straightforwardly checked whether the locus is 599 significantly associated with the multivariate trait in the replication cohort using the same

test as in the discovery stage. The replication threshold was set as $P < \frac{0.05}{(7+16)} = 0.0021$, 600 601 where 7 is the number of previously identified but not replicated loci and 16 is the 602 number of novel loci. Then we checked whether the effect direction is consistent between the two cohorts, using the phenotype score approach²⁹. Next, we evaluated 603 604 the concordance of multivariate effect between two samples using Pearson and 605 Kendall's correlation coefficients. We considered an association of the locus replicated if 606 it had successfully passed MANOVA and phenotype score steps of replication. The 607 multivariate effect of the locus replicated if it additionally had passed both Pearson's 608 and Kendall's correlation steps of replication (Supplementary Note, Supplementary Table 5b, and Supplementary Fig. 2). Phenotype score-based replication was 609 performed as in Shadrina et al⁴¹. For each lead pair of SNP and trait group phenotype, 610 611 we extracted coefficients of the linear combination of genotype onto multiple atomic 612 phenotypes, estimated for discovery cohort. We used them to construct the 613 corresponding trait group phenotypes for further testing of an association between the 614 lead SNPs and the derived linear combinations (see Supplementary Note for details). A 615 locus was replicated if the association of the SNP with the constructed linear 616 combination had the same direction of effect as in the discovery cohort and passed the 617 threshold of P < 0.0021.

To evaluate the similarity between estimates of multivariate genetic effects from discovery and replication cohorts across multiple traits, we used an MC-based approach implemented in MultiABEL package (MV.cor.test() function)²⁸. For both Pearson's and Kendall's correlation coefficients, we considered a multivariate effect for a specific SNP replicated if the 95% confidence intervals didn't include zero.

623 SNP-based heritability and polygenic scores

624 SNP-based heritability was estimated using the LD Score regression software⁴⁴ embedded in the GWAS-MAP platform⁷⁹. We used pre-computed LD scores that were 625 626 calculated from the European-ancestry samples in the 1000 Genomes Project. Only the 627 1,176,189 HapMap3 SNPs were included with a MAF > 0.05. For the purpose of 628 heritability estimation and further post-GWAS analyses, we generated GWAMA 629 summary statistics for the samples of European descent with N = 10,172. We used 630 GWAMA summary statistics for the analysis in order to use the largest data set with 631 homogeneous ancestry.

632 SBayesR method reweights the effect of each variant according to the marginal 633 estimate of its effect size, statistical strength of association, the degree of correlation

634 between the variant and other variants nearby, and tuning parameters. This method 635 requires a compatible LD matrix file computed using individual-level data from a 636 reference population. For these analyses, we used publicly available shrunk sparse 637 GCTB LD matrix including 1.1 million HapMap3 variants and computed from a random set of 50,000 individuals of European ancestry from the UKB data set^{47,80}. SBayesR 638 639 (qctb 2.03) was run for each chromosome separately, and with the default parameters 640 except for the number of iterations (N = 5,000) and options for the stability of the 641 algorithm (Supplementary Table 7). The prediction accuracy was defined as the 642 proportion of the variance of a phenotype that is explained by PGS values (R2). To calculate PGS based on the PGS model, we used PLINK2 software⁸¹, where PGS 643 644 values were calculated as a weighted sum of allele counts. Out-of-sample prediction 645 accuracy was evaluated using samples from the CEDAR cohort that were not used for 646 discovery or replication.

647 Prioritization of candidate genes in found loci

For the purpose of post-GWAS analyses, we generated GWAMA summary statistics for 648 649 the samples of European descent (N = 10,172). GWAMA summary statistics passed the 650 same QC procedure as discovery and replication GWAMA. We applied an ensemble of 651 methods to prioritize plausible candidate genes in the loci with found and replicated 652 glyQTL (32 in univariate and 8 in multivariate analysis). We applied eight approaches to 653 prioritize the most likely effector genes: (1) prioritization of the nearest gene; (2) prioritization of genes with known role in biosynthesis of N-glycans; (3) genes of 654 655 congenital disorders of glycosylation; (4) genes with direct experimental support for 656 regulation of protein N-glycosylation; (5) prioritization of genes containing variants in strong LD ($r^2 \ge 0.8$) with the lead variant, which are protein truncating variants 657 (annotated by Variant Effect Predictor, VEP⁴⁹) or predicted to be damaging by FATHMM 658 XF⁵⁰, FATHMM InDel⁵¹; (6) prioritization of genes whose eQTL and/or (7) pQTL are 659 660 colocalized with glyQTL; (8) prioritization of genes based on the gene set and tissue/cell 661 type enrichment, calculated by Data-driven Expression Prioritized Integration for Complex Traits (DEPICT) framework³¹. We prioritized the most likely 'causal gene' for 662 663 each association using a consensus-based approach, selecting the gene with the 664 highest, unweighted sum of evidence across all eight predictors. In the case of equality 665 of the scores for two genes, we prioritized both genes.

666 Functional annotation of genetic variants

667 We inferred the possible molecular consequences of genetic variants in glyQTLs. We focused on variants in LD with lead (for univariate and multivariate signals) and sentinel 668 669 variants (for univariate signals) picked by COJO. We created a "long list" of putative 670 causal variants using PLINK version 1.9 (--show-tags option), applied to whole genome 671 re-sequenced data for 503 European ancestry individuals (1000 Genomes phase 3 672 version 5 data). The size of the window to find the LD in both cases was equal to 500 kb. The default value of $r^2 > 0.8$ was taken as a threshold to include SNPs into the 673 674 credible sets, Ensembl Variant Effect Predictor (VEP) (Supplementary Table 6e) and by 675 FATHMM-XF (Supplementary Table 6c), FATHMM-INDEL (Supplementary Table 6d) to 676 reveal pathogenic point mutations.

677 Genes of N-glycan biosynthesis and Congenital Disorders of Glycosylation

678 We searched for the genes encoding glycosyltransferases - enzymes, with a known role in N-glycan biosynthesis⁸², located in the ±250 Kb-vicinity of the lead SNPs in 679 680 glyQTLs. Additionally, we prioritized genes with known mutations, that cause Congenital 681 Disorder of Glycosylation according to MedGen database (https://www.ncbi.nlm.nih.gov/medgen/76469) that are located in the vicinity of ±250 kb 682 683 from the lead SNPs.

684 Colocalization with eQTL and pQTL

685 To find potential pleiotropic effects of glyQTL on gene expression levels in relevant 686 tissues, we applied Summary data-based Mendelian Randomization (SMR) analysis followed by the Heterogeneity in Dependent Instruments (HEIDI)³² on expression of 687 quantitative trait loci (eQTLs) obtained from Westra Blood eQTL collection⁸³ (peripheral 688 blood), GTEx (version 7) eQTL collection⁸⁴ (liver, whole blood), CEDAR eQTL 689 collection⁵³ (CD19+ B lymphocytes, CD8+ T lymphocytes, CD4+ T lymphocytes, CD14+ 690 691 monocytes, CD15+ granulocytes) and on protein guantitative trait loci (pQTLs) using SomaLogic datasets^{85,86}. As outcome variable we used univariate association results for 692 the N-glycome trait with the most significant association; in the case of glyQTLs 693 694 replicated only in multivariate analysis, we used summary statistics for the most 695 associated univariate trait as the primary trait in the analysis.

696 The results of the SMR test were considered statistically significant if $P_{adj} < 0.05$ 697 (Benjamini-Hochberg adjusted *P*). The significance threshold for HEIDI tests was set at 698 P = 0.05 (P < 0.05 corresponds to the rejection of the pleiotropy hypothesis) 699 (Supplementary Table 6f, 6g).

700 DEPICT

Gene prioritization and gene set and tissue/cell type enrichment analyses were performed using the Data-driven Expression Prioritized Integration for Complex Traits framework (DEPICT)³¹. DEPICT analysis was conducted for SNPs associated with any N-glycosylation trait at $P < 5 \times 10^{-8}/28$ in univariate analysis and with any Nglycosylation trait group at $P < 5 \times 10^{-8}/21$ in multivariate analysis. The significance threshold for DEPICT analysis was set at False Discovery Rate *FDR* < 0.20 (Supplementary Table 6h, 6i, 6j).

708 Colocalization with TF and IgG

In this study, colocalization analysis $(SMR-\theta)^{53}$ was conducted for total plasma, 709 710 IgG and TF glyQTLs. The analysis was restricted to loci that were a) previously implicated in TF GWAS⁴² (4 loci); IgG GWAS⁴⁰ (15 loci); both (2 loci) (Supplementary 711 Table 5d), b) reached genome-wide significance in the GWAMA of European descent 712 713 (N=10,172), c) replicated in this study. Statistic θ is a weighted correlation, whose 714 computation requires information on p-values and effect direction. The high absolute 715 value (e. g. $|\theta| > 0.7$) means the locus likely has a pleiotropic effect on investigated 716 traits.

717

718 Pleiotropy with disease

To study potential pleiotropic effects on a range of traits associated with various medical conditions SMR/HEIDI analysis was carried out similarly to that for colocalization with eQTL and pQTL.

722 Summary statistics for complex and medical conditions-related traits were Biobank⁸⁷, UK CARDIoGRAM 723 obtained the from the Consortium 724 (http://www.cardiogramplusc4d.org/), the Psychiatric Genomics consortium (https://pgc.unc.edu/) and other trait collections from other studies (see Supplementary 725 726 Table 9 for the full list of the traits analyzed). We conducted analysis separately for the 727 disease-related traits and other complex traits.

728

729 Associations between PGS for plasma N-glycosylation traits and disease phenotypes

To test the associations between the 117 human plasma N-glycosylation traits and ICD-10 disease phenotypes, we used logistic regression considering PGS for each glycan trait as a predictor for each disease phenotype in turn.

733 The list of the diseases was taken from medical histories and questionaries 734 obtained from non-related UK Biobank participants of European descent for which we 735 had PGS for N-glycosylation traits calculated (N = 374,303). All medical codes were 736 preliminary filtered by prevalence (> 0.5% and < 99.5%). For this analysis we used 167 737 groups of codes that fall into Chapters I-XV of the UK Biobank classification of 738 phenotypes. These codes describe a wide range of phenotypes including infectious 739 diseases, endocrine, nutritional and metabolic diseases, diseases of the nervous 740 system, diseases of the circulatory, respiratory, digestive and other systems, etc.

To perform logistic regression analyses we used the standard glm() function in R v.4.2.2. programming language. We included sex, age, batch number and first ten principal components of the kinship matrix (PC 1-10) as covariates in addition to the PGS predictor. Finally, we filtered out the results not passing the significance threshold for the association of $P < 0.05/(28 \times 167) = 1.07 \times 10^{-5}$, where 28 is the number of plasma N-glycome principal components explaining over 99% of the 117 Nglycosylation traits variation, and 167 is the numbers of ICD-10 codes.

748

749 Mendelian Randomization and Sensitivity Analyses

In the previous step we identified 64 pairs of associated disease phenotypes and plasma N-glycosylation traits. To investigate the causal relationships between these traits we performed a bidirectional two-sample MR analysis³³: for each pair we performed two MR analyses using the glycosylation trait as exposure and the disease as outcome and *vice versa*.

As the sources of the summary statistics for MR analyses, we used the largest available GWAMA for plasma N-glycosylation traits in a cohort of European descent described previously in the current study (N = 10,172) and GWAS available from the UK Biobank database (for more details about these cohorts see Supplementary Table 14).

759 The framework of the two-sample MR was specified before the analysis. Genetic 760 IVs for the two sample MR were identified as follows. First, the set of SNPs present both 761 in the GWAS for the exposure and outcome traits was selected. Then for this 762 overlapping set of SNPs in the GWAS for the exposure trait we performed clumping for 763 independence using PLINK2⁸¹ within a 10,000 kb window. Additional parameters for clumping included an $r^2 > 0.001$ threshold for correlation, IVs with minor allele 764 frequency MAF < 0.05 were excluded. When plasma N-glycosylation traits were 765 766 considered as exposures, P threshold for clumping was defined as $5 \times 10^{-8}/28 =$

1.79 \times 10⁻⁹ (28 - number of plasma N-glycome principal components explaining over 99% of the 117 N-glycosylation traits variation). When the disease phenotypes were considered as exposure, this threshold was set at 5 \times 10⁻⁸/14 = 3.57 \times 10⁻⁹ (14 number of disease phenotypes significantly associated with at least one plasma Nglycosylation trait in the logistic regression analysis).

772 Summary statistics for IVs in the exposure and outcome GWAS data were processed using the TwoSampleMR R package³³: the data were harmonized excluding 773 774 ambiguous/triallelic SNPs. Only the pairs where at least 2 IVs were available for the 775 exposure trait were considered for the further analysis. MR analysis was performed 776 using mr_report() function from the TwoSampleMR R package. Significance thresholds for the MR results were set as $\frac{0.05}{49} = 0.001$ for the analysis of 49 traits pairs where 777 glycans were considered as exposures, and as $\frac{0.05}{64} = 0.00078$ for the analysis of the 64 778 779 pairs where diseases were considered as exposures. If at least one of the MR methods 780 used (Inverse variance weighted, MR Egger, Weighted median, Weighted mode, or 781 Simple mode) produced a statistically significant causal estimate, that pair of traits was 782 selected for the follow-up sensitivity analyses.

Follow-up sensitivity analyses included those automatically implemented in the mr_report() function, such as heterogeneity tests, test for directional horizontal pleiotropy, leave-one-out analysis, forest plot and funnel plot.

In addition to the sensitivity analyses described above, for the pairs where plasma N-glycosylation traits were used as exposures, since the number of IVs was very low (2-3 SNPs), we performed colocalization analysis (SMR-HEIDI) for each of the IVs. The results of the SMR test were considered statistically significant if Benjamini-Hochberg adjusted P < 0.05. The significance threshold for HEIDI tests was set at P = 0.05 which corresponds to the rejection of the pleiotropy hypothesis.

For the pairs where the disease was the upstream exposure trait (disorders of lipoprotein metabolism and other lipidaemias, E78) and 27 IVs were available, we identified pleiotropic IVs using MR-PRESSO R package, detecting the IVs for which *P* of the test for outliers in MR-PRESSO were < 1. Then we repeated the MR analysis as described above excluding these SNPs.

797 Data availability

The full genome-wide summary association statistics for the 117 N-glycome traits will be made publicly available **upon publication of the paper**. The data generated in the

800 secondary analyses of this study are included with this article in the Supplementary

801 Tables.

802 Acknowledgements

803 The work of S.Sh., A.T., D.M., A.S., Y.S.A. was supported by the Research Program at 804 the Moscow State University (MSU) Institute for Artificial Intelligence. The study was 805 conducted using the UK Biobank resource under application #59345. The work of E.E., Y.A.T was supported by the budget project of the Institute of Cytology and Genetics 806 807 FWNR-2022-0020. European Community's Seventh Framework Programme funded 808 project PainOmics (602736). TwinsUK is funded by the Wellcome Trust, Medical 809 Research Council, Versus Arthritis, European Union Horizon 2020, Chronic Disease 810 Research Foundation (CDRF), Zoe Ltd and the National Institute for Health Research 811 (NIHR) Clinical Research Network (CRN) and Biomedical Research Centre based at 812 Guy's and St Thomas' NHS Foundation Trust in partnership with King's College 813 London. The TwinsUK Study was approved by London-Westminster Research Ethics Committee (REC reference EC04/015), and Guy's and St Thomas' NHS Foundation 814 815 Trust Research and Development (R&D). The TwinsUK BioBank was approved by the 816 HRA - Liverpool East Research Ethics Committee (REC reference 19/NW/0187), IRAS 817 ID 258513. All participants provide written, informed consent. We thank Toma Keser, 818 Mirna Šimurina, Marija Vilaj, Jerko Štambuk, Ivan Gudelj, Thomas S. Klarić, Jasminka Krištić, Jelena Šimunović, Julija Jurić, Ana Momčilović, Najda Rudman, and Maja Hanić 819 820 for their assistance with glycan analysis.

- 821
- 822

823 Author contributions

824 S.Sh. coordinated this study; S.Sh., A.T., O.Z., D.M., A.S., E.E., E.T., A.N., S.F., N.A.P., 825 Y.A.T. contributed to the design of the study, carried out statistical analysis; A.T., D.M., A.S., E.T., O.Z., S.Sh. produced the figures; S.Sh., A.T., O.Z., D.M., A.S., Y.A.T., 826 827 contributed to interpretation of the results; S.Sh., A.T., O.Z., D.M., A.S., A.N. and Y.S.A. 828 wrote the first version of the manuscript; S.Sh., A.T., O.Z., D.M., A.S., and Y.S.A. wrote the revised second version of the manuscript; S.Sh., E.T., E.E., S.F., V.V. and Y.A.T. 829 contributed to data harmonization and quality control; F.V., I.T.-A., T.Š. contributed to 830 plasma N-glycome measurements and guality contol; M.M., T.S. analyzed TwinsUK 831 832 dataset and contributed to interpretation of the results; M.T., M.D. analyzed SOCCS 833 dataset and contributed to interpretation of the results; L.K., F.W., D.P., J. Van Z., M.A.

designed PainOmics study and contributed to interpretation of the results; K.S. analyzed
QMDiab dataset and contributed to interpretation of the results; M.G. designed CEDAR
study and contributed to interpretation of the results; C.W. and M.B.S. contributed to the
data collection and analyses of EPIC-Potsdam and to the interpretation of results;
Y.S.A. and G.L. conceived and oversaw the study, contributed to the design and
interpretation of the results; all co-authors contributed to the final manuscript revision.

840 Competing interests statement

Y.S.A. is a full-time employee of GSK PLC and receives salary and stock options as
compensation. Y.S.A. is a founder and co-owner of PolyKnomics BV, a private
organization, providing services, research and development in the field of computational
and statistical genomics. G.L. is a founder and owner of Genos Ltd, a biotech company
that specializes in glycan analysis and has several patents in the field. O.Z., T.Š., F.V.
and I.T.-A are employees of Genos Ltd. All other authors declare no conflicts of interest.
Other authors declare no competing financial interests.

- 848 References
- 1. Apweiler, R., Hermjakob, H. & Sharon, N. On the frequency of protein glycosylation,
- as deduced from analysis of the SWISS-PROT database. *Biochim Biophys Acta*
- **1473**, 4–8 (1999).
- 852 2. Clerc, F. *et al.* Human plasma protein N-glycosylation. *Glycoconj J* 33, 309–343
 853 (2016).
- 3. Ohtsubo, K. & Marth, J. D. Glycosylation in cellular mechanisms of health and
 disease. *Cell* **126**, 855–867 (2006).
- 4. Skropeta, D. The effect of individual N-glycans on enzyme activity. *Bioorg Med Chem* 17, 2645–2653 (2009).
- 5. Takeuchi, H. *et al.* O-Glycosylation modulates the stability of epidermal growth
 factor-like repeats and thereby regulates Notch trafficking. *J Biol Chem* 292, 15964–
 15973 (2017).
- 861 6. Lauc, G., Pezer, M., Rudan, I. & Campbell, H. Mechanisms of disease: The human
 862 N-glycome. *Biochim Biophys Acta* 1860, 1574–1582 (2016).

- 863 7. Reily, C., Stewart, T. J., Renfrow, M. B. & Novak, J. Glycosylation in health and
- disease. *Nat Rev Nephrol* **15**, 346–366 (2019).
- 865 8. Dotz, V. & Wuhrer, M. N-glycome signatures in human plasma: associations with 866 physiology and major diseases. *FEBS Lett* **593**, 2966–2976 (2019).
- 867 9. Gudelj, I., Lauc, G. & Pezer, M. Immunoglobulin G glycosylation in aging and
 868 diseases. *Cell Immunol* 333, 65–79 (2018).
- 10. Dwek, R. A., Butters, T. D., Platt, F. M. & Zitzmann, N. Targeting glycosylation as a
 therapeutic approach. *Nat Rev Drug Discov* 1, 65–75 (2002).
- 11. Rodríguez, E., Schetters, S. T. T. & van Kooyk, Y. The tumour glyco-code as a
- 872 novel immune checkpoint for immunotherapy. *Nat Rev Immunol* 18, 204–211
 873 (2018).
- 12. Pagan, J. D., Kitaoka, M. & Anthony, R. M. Engineered Sialylation of Pathogenic
 Antibodies In Vivo Attenuates Autoimmune Disease. *Cell* **172**, 564-577.e13 (2018).
- 13. Van Landuyt, L., Lonigro, C., Meuris, L. & Callewaert, N. Customized protein
- 877 glycosylation to improve biopharmaceutical function and targeting. *Curr Opin*878 *Biotechnol* 60, 17–28 (2019).
- 14. Johannssen, T. & Lepenies, B. Glycan-Based Cell Targeting To Modulate Immune
 Responses. *Trends in Biotechnology* 35, 334–346 (2017).
- 15. Paderi, J., Prestwich, G. D., Panitch, A., Boone, T. & Stuart, K. Glycan
 Therapeutics: Resurrecting an Almost Pharma-Forgotten Drug Class. *Advanced Therapeutics* 1, 1800082 (2018).
- 16. Adamczyk, B., Tharmalingam, T. & Rudd, P. M. Glycans as cancer biomarkers. *Biochimica et Biophysica Acta (BBA) General Subjects* 1820, 1347–1353 (2012).
- 17. Thanabalasingham, G. *et al.* Mutations in HNF1A result in marked alterations of
 plasma glycan profile. *Diabetes* 62, 1329–1337 (2013).

- 18. Shinohara, Y., Furukawa, J. & Miura, Y. Glycome as Biomarkers. in *General Methods in Biomarker Research and their Applications* (eds. Preedy, V. R. & Patel,
 V. B.) 111–140 (Springer Netherlands, Dordrecht, 2015). doi:10.1007/978-94-007-
- 891 7696-8_23.
- 19. Taniguchi, N. Handbook of Glycosyltransferases and Related Genes, Second
 Edition // Handbook of Glycosyltransferases and Related Genes. (2014).
- 20. Lauc, G., Vojta, A. & Zoldoš, V. Epigenetic regulation of glycosylation is the quantum mechanics of biology. *Biochim Biophys Acta* **1840**, 65–70 (2014).
- 896 21. Moremen, K. W., Tiemeyer, M. & Nairn, A. V. Vertebrate protein glycosylation:
- diversity, synthesis and function. *Nat. Rev. Mol. Cell Biol.* **13**, 448–462 (2012).
- 898 22. Knezevic, A. *et al.* Variability, heritability and environmental determinants of human
 899 plasma N-glycome. *J. Proteome Res.* 8, 694–701 (2009).
- 900 23. Lombard, V., Golaconda Ramulu, H., Drula, E., Coutinho, P. M. & Henrissat, B. The
- 901 carbohydrate-active enzymes database (CAZy) in 2013. *Nucleic Acids Res* 42,
 902 D490-495 (2014).
- 24. Lauc, G., Rudan, I., Campbell, H. & Rudd, P. M. Complex genetic regulation of
 protein glycosylation. *Mol Biosyst* 6, 329–335 (2010).
- 905 25. Timoshchuk, A., Sharapov, S. & Aulchenko, Y. S. Twelve Years of Genome-Wide
- 906 Association Studies of Human Protein N-Glycosylation. *Engineering* (2023)
 907 doi:10.1016/j.eng.2023.03.013.
- 908 26. Krištić, J., Sharapov, S. Z. & Aulchenko, Y. S. Quantitative Genetics of Human
 909 Protein N-Glycosylation. *Adv Exp Med Biol* **1325**, 151–171 (2021).
- 910 27. Reiding, K. R. et al. High-throughput Serum N-Glycomics: Method Comparison and
- 911 Application to Study Rheumatoid Arthritis and Pregnancy-associated Changes. *Mol.*
- 912 *Cell. Proteomics* **18**, 3–15 (2019).

- 913 28. Shen, X. et al. Multivariate discovery and replication of five novel loci associated
- 914 with Immunoglobulin G N-glycosylation. *Nat Commun* **8**, 447 (2017).
- 915 29. Ning, Z. et al. Nontrivial Replication of Loci Detected by Multi-Trait Methods. Front
- 916 *Genet* **12**, 627989 (2021).
- 917 30. Pasaniuc, B. & Price, A. L. Dissecting the genetics of complex traits using summary
- 918 association statistics. *Nat. Rev. Genet.* **18**, 117–127 (2017).
- 919 31. Pers, T. H. et al. Biological interpretation of genome-wide association studies using
- 920 predicted gene functions. *Nat Commun* **6**, 5890 (2015).
- 921 32. Zhu, Z. et al. Integration of summary data from GWAS and eQTL studies predicts
- 922 complex trait gene targets. *Nat. Genet.* **48**, 481–487 (2016).
- 33. Hemani, G. *et al.* The MR-Base platform supports systematic causal inference
 across the human phenome. *Elife* 7, (2018).
- 925 34. Lauc, G. et al. Genomics Meets Glycomics-The First GWAS Study of Human N-
- 926 Glycome Identifies HNF1α as a Master Regulator of Plasma Protein Fucosylation.

927 *PLoS genetics* (2010) doi:10.1371/journal.pgen.1001256.

928 35. Huffman, J. E. et al. Polymorphisms in B3GAT1, SLC9A9 and MGAT5 are

associated with variation within the human plasma N-glycome of 3533 European
adults. *Hum Mol Genet* 20, 5000–5011 (2011).

- 36. Sharapov, S. et al. Defining the Genetic Control of Human Blood Plasma NGlycome Using Genome-Wide Association Study. (2018). doi:10.1101/365486.
- 933 37. Sharapov, S. Z. *et al.* Replication of 15 loci involved in human plasma protein N934 glycosylation in 4802 samples from four cohorts. *Glycobiology* **31**, 82–88 (2021).
- 935 38. Lauc, G. et al. Loci associated with N-glycosylation of human immunoglobulin G
- show pleiotropy with autoimmune diseases and haematological cancers. *PLoS Genet.* 9, e1003225 (2013).

- 938 39. Wahl, A. et al. Genome-Wide Association Study on Immunoglobulin G Glycosylation
- 939 Patterns. Front. Immunol. 9, 277 (2018).
- 940 40. Klarić, L. et al. Glycosylation of immunoglobulin G is regulated by a large network of
- genes pleiotropic with inflammatory diseases. *Sci Adv* **6**, eaax0301 (2020).
- 942 41. Shadrina, A. S. et al. Multivariate genome-wide analysis of immunoglobulin G N-
- 943 glycosylation identifies new loci pleiotropic with immune function. Hum Mol Genet
- **30**, 1259–1270 (2021).
- 945 42. Landini, A. *et al.* Genetic regulation of post-translational modification of two distinct
 946 proteins. *Nat. Commun.* 13, 1586 (2022).
- 947 43. Zaytseva, O. O. et al. Investigation of the causal relationships between human IgG
- 948 N-glycosylation and 12 common diseases associated with changes in the IgG N-
- glycome. *Hum Mol Genet* **31**, 1545–1559 (2022).
- 950 44. Bulik-Sullivan, B. K. *et al.* LD Score regression distinguishes confounding from
 951 polygenicity in genome-wide association studies. *Nat Genet* 47, 291–295 (2015).
- 952 45. Yang, J. et al. Conditional and joint multiple-SNP analysis of GWAS summary
- 953 statistics identifies additional variants influencing complex traits. *Nat. Genet.* **44**,
- 954 369–75, S1-3 (2012).
- 46. Zaytseva, O. O. *et al.* Heritability of Human Plasma N-Glycome. *J Proteome Res* 19,
 85–91 (2020).
- 47. Lloyd-Jones, L. R. *et al.* Improved polygenic prediction by Bayesian multiple
 regression on summary statistics. *Nat Commun* **10**, 5086 (2019).
- 959 48. Aragam, K. G. et al. Discovery and systematic characterization of risk variants and
- genes for coronary artery disease in over a million participants. *Nat Genet* 54, 1803–
 1815 (2022).
- 962 49. McLaren, W. *et al.* The Ensembl Variant Effect Predictor. *Genome Biol* **17**, 122
 963 (2016).

- 964 50. Rogers, M. et al. FATHMM-XF: accurate prediction of pathogenic point mutations
- 965 via extended features. *Bioinform.* (2018) doi:10.1093/bioinformatics/btx536.
- 966 51. Ferlaino, M. et al. An integrative approach to predicting the functional effects of
- 967 small indels in non-coding regions of the human genome. *BMC Bioinformatics* 18,
 968 442 (2017).
- 969 52. Stacey, D. *et al.* ProGeM: a framework for the prioritization of candidate causal 970 genes at molecular quantitative trait loci. *Nucleic Acids Res* **47**, e3 (2019).
- 971 53. Momozawa, Y. *et al.* IBD risk loci are enriched in multigenic regulatory modules
 972 encompassing putative causative genes. *Nature Communications* 9, (2018).
- 973 54. Giambartolomei, C. et al. Bayesian test for colocalisation between pairs of genetic
- 974 association studies using summary statistics. *PLoS Genet* **10**, e1004383 (2014).
- 55. Williams, F. M. K. *et al.* Ischemic stroke is associated with the ABO locus: the
 EuroCLOT study. *Ann Neurol* **73**, 16–31 (2013).
- 977 56. Sabotta, C. M. et al. Genetic variants associated with circulating liver injury markers
- 978 in Mexican Americans, a population at risk for non-alcoholic fatty liver disease. *Front*
- 979 *Genet* **13**, 995488 (2022).
- 57. Ewald, D. R. & Sumner, S. C. J. Blood type biochemistry and human disease. *Wiley*Interdiscip Rev Syst Biol Med 8, 517–535 (2016).
- 58. Verbanck, M., Chen, C.-Y., Neale, B. & Do, R. Detection of widespread horizontal
 pleiotropy in causal relationships inferred from Mendelian randomization between
 complex traits and diseases. *Nat Genet* **50**, 693–698 (2018).
- 59. Fairfield, C. J. *et al.* Genome-Wide Association Study of NAFLD Using Electronic
 Health Records. *Hepatology Communications* 6, 297 (2022).
- 987 60. Vujkovic, M. et al. A multiancestry genome-wide association study of unexplained
- 988 chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological
- 989 and radiological validation. *Nat Genet* **54**, 761–771 (2022).

- 990 61. Hülsmeier, A. J., Tobler, M., Burda, P. & Hennet, T. Glycosylation site occupancy in
- health, congenital disorder of glycosylation and fatty liver disease. *Sci Rep* 6, 33927
 (2016).
- 993 62. Verhelst, X. et al. Protein Glycosylation as a Diagnostic and Prognostic Marker of
- 994 Chronic Inflammatory Gastrointestinal and Liver Diseases. *Gastroenterology* 158,
 995 95–110 (2020).
- 63. Blomme, B., Van Steenkiste, C., Callewaert, N. & Van Vlierberghe, H. Alteration of
 protein glycosylation in liver diseases. *Journal of Hepatology* **50**, 592–603 (2009).
- 998 64. Gong, J., Tu, W., Liu, J. & Tian, D. Hepatocytes: A key role in liver inflammation.
- 999 Front. Immunol. **13**, (2023).
- 1000 65. Radovani, B. & Gudelj, I. N-Glycosylation and Inflammation; the Not-So-Sweet 1001 Relation. *Front Immunol* **13**, 893365 (2022).
- 1002 66. Kettunen, J. *et al.* Genome-wide study for circulating metabolites identifies 62 loci
 1003 and reveals novel systemic effects of LPA. *Nat Commun* **7**, 11122 (2016).
- 1004 67. Kiryluk, K., Novak, J. & Gharavi, A. G. Pathogenesis of Immunoglobulin A
- 1005 Nephropathy: Recent Insight from Genetic Studies. *Annual Review of Medicine* 64,
 1006 339–356 (2013).
- 1007 68. Kiss, M. G. *et al.* Complement Factor H Modulates Splenic B Cell Development and
 1008 Limits Autoantibody Production. *Front Immunol* **10**, 1607 (2019).
- 1009 69. Dotz, V. et al. O- and N-Glycosylation of Serum Immunoglobulin A is Associated
- 1010 with IgA Nephropathy and Glomerular Function. *J Am Soc Nephrol* 32, 2455–24651011 (2021).
- 1012 70. Momčilović, A. *et al.* Simultaneous Immunoglobulin A and G Glycopeptide Profiling
 1013 for High-Throughput Applications. *Anal Chem* **92**, 4518–4526 (2020).
- 1014 71. Demus, D. et al. Large-Scale Analysis of Apolipoprotein CIII Glycosylation by
- 1015 Ultrahigh Resolution Mass Spectrometry. *Frontiers in Chemistry* **9**, (2021).

- 1016 72. Avila Cobos, F., Alquicira-Hernandez, J., Powell, J. E., Mestdagh, P. & De Preter, K.
- Benchmarking of cell type deconvolution pipelines for transcriptomics data. *Nat Commun* **11**, 5650 (2020).
- 1019 73. Akmačić, I. T. *et al.* High-throughput glycomics: optimization of sample preparation.
- 1020 Biochemistry (Mosc.) **80**, 934–942 (2015).
- 1021 74. Dieterle, F., Ross, A., Schlotterbeck, G. & Senn, H. Probabilistic quotient 1022 normalization as robust method to account for dilution of complex biological
- 1023 mixtures. Application in 1H NMR metabonomics. *Anal Chem* **78**, 4281–4290 (2006).
- 1024 75. Benedetti, E. et al. Systematic Evaluation of Normalization Methods for Glycomics
- 1025 Data Based on Performance of Network Inference. *Metabolites* **10**, 271 (2020).
- 1026 76. McCarthy, S. et al. A reference panel of 64,976 haplotypes for genotype imputation.
- 1027 Nat Genet **48**, 1279–1283 (2016).
- 1028 77. 1000 Genomes Project Consortium *et al.* A global reference for human genetic
 1029 variation. *Nature* 526, 68–74 (2015).
- 1030 78. Li, J. & Ji, L. Adjusting multiple testing in multilocus analyses using the eigenvalues
 1031 of a correlation matrix. *Heredity (Edinb)* 95, 221–227 (2005).
- 1032 79. Shashkova, T. I. et al. The GWAS-MAP platform for aggregation of results of
- 1033 genome-wide association studies and the GWAS-MAP|homo database of 70 billion
- 1034 genetic associations of human traits. *Vavilovskii Zhurnal Genet Selektsii* 24, 876–
 1035 884 (2020).
- 1036 80. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic
 1037 data. *Nature* 562, 203–209 (2018).
- 1038 81. Chen, Z.-L. *et al.* A high-speed search engine pLink 2 with systematic evaluation for
 1039 proteome-scale identification of cross-linked peptides. *Nat Commun* **10**, 3404
 1040 (2019).

- 1041 82. Narimatsu, Y. et al. An Atlas of Human Glycosylation Pathways Enables Display of
- the Human Glycome by Gene Engineered Cells. *Mol Cell* **75**, 394-407.e5 (2019).
- 1043 83. Westra, H.-J. et al. Systematic identification of trans eQTLs as putative drivers of
- 1044 known disease associations. *Nat. Genet.* **45**, 1238–1243 (2013).
- 1045 84. GTEx Consortium et al. Genetic effects on gene expression across human tissues.
- 1046 *Nature* **550**, 204–213 (2017).
- 1047 85. Suhre, K. *et al.* Connecting genetic risk to disease end points through the human
 1048 blood plasma proteome. *Nat Commun* 8, 14357 (2017).
- 1049 86. Sun, B. B. *et al.* Genomic atlas of the human plasma proteome. *Nature* **558**, 73–79
- 1050 (2018).
- 1051 87. Canela-Xandri, O., Rawlik, K. & Tenesa, A. An atlas of genetic associations in UK
 1052 Biobank. *Nat Genet* 50, 1593–1599 (2018).
- 1053 88. Lachmann, A. et al. Massive mining of publicly available RNA-seq data from human

1054 and mouse. *Nat Commun* **9**, 1366 (2018).

1055

1056 Legends to Main Figures

1057 Figure 1: Discovered loci. (a) Associations of 59 loci with 138 glycomic traits labeled 1058 by the prioritized candidate or nearest gene names. Marked black: loci are discovered 1059 and replicated in this work; red: discovered, but not replicated in this work. In total, 117 1060 univariate traits were analyzed (Supplementary Table 3a), but for two of them, no 1061 genome-wide significant associations were found. Univariate traits are grouped into 4 1062 categories: glycans mostly linked to immunoglobulins (green), glycans mostly linked to 1063 non-immunoglobulin proteins (purple), glycans linked to both types of proteins (orange), 1064 not classified glycans (gray). The details of glycan classification are described in 1065 Supplementary Note. Also, the results from analysis of 21 multivariate traits (turquoise) 1066 are presented. The multivariate traits were defined based on biochemical similarities 1067 between 36 directly measured total plasma N-glycan traits (Supplementary Table 3b).

(b) A network view of associations between loci and glycan traits. Rectangular nodesrepresent genetic loci labeled with the names of the prioritized candidate or nearest

1070 genes; circle nodes represent glycan traits. Lines represent significant genetic
1071 associations between locus and specific glycans. The colors of circle nodes are
1072 consistent with those in (a).

1073 Symbol \circ next to the candidate gene indicates that the locus was previously discovered 1074 in immunoglobulin G N-glycome GWASs; Symbol • — the locus was previously 1075 discovered in transferrin N-glycome GWAS, as reviewed in ²⁵.

1076

1077 **Figure 2: Candidate genes.** (a) Gene expression of the candidate genes in two 1078 relevant cell types - hepatocytes and plasma cells. Expression levels are represented 1079 as the median logarithm of transcripts per million. The data for hepatocytes (N = 513) 1080 and plasma cells (N = 53) samples were obtained from the ARCHS4 portal ⁸⁸.

1081 (b) Predictors indicating the 32 candidate genes. Gene order corresponds to (a). The 1082 identical superscripts denote candidate genes inside one locus. Full details of the gene 1083 prioritization are presented in Supplementary Table 6b. Symbol \circ next to the candidate 1084 gene indicates that the locus was previously discovered in immunoglobulin G N-1085 Glycome GWASs; Symbol • — the locus was previously discovered in transferrin N-1086 Glycome GWAS, as reviewed in ²⁵.

1087

1088 Figure 3: Phenome-wide colocalization results for significant and replicated loci.

(a) Heatmap of traits with pleiotropic associations (PadjSMR < 0.05 and PHEIDI >=
0.05). The row order is determined by clustering on the set of significantly colocalized
traits (Jaccard similarity index and Ward's linkage). For the sake of readability similar
traits are grouped into broader categories, e.g., such traits as fat-free mass of left leg,
trunk fat mass are combined under the name "Body mass". The numbers in the cells
represent the number of pleiotropic associations, grouped under a common name,
confirmed for a given locus. Color does not carry semantic load.

(b) Heatmap providing details of pleiotropic associations with diseases from (a). Colordoes not carry semantic load.

1098 (c) Count of traits for each locus with pleiotropic associations.

Symbol o next to the candidate gene indicates that the locus was previously discovered
in immunoglobulin G N-Glycome GWASs; Symbol • — the locus was previously
discovered in transferrin N-Glycome GWAS, as reviewed in ²⁵. Abbreviations: BMI: body
mass index; BN: benign neoplasm; CLL: chronic leukocytic leukemia; T1D: type 1
diabetes; T2D: type 2 diabetes; BD: bipolar disorder; BP: blood pressure; MI:
myocardial infarction; CAD: coronary artery's disease; CD: Crohn disease; IBD:

1105 Inflammatory bowel disease; IHD: Ischemic heart disease; NC: non-cancer, non-I: non-

1106 iodine dependent; RA: rheumatoid arthritis; SCZ: schizophrenia; UC: ulcerative colitis.

1107

Figure 4: Significant associations between PGS for plasma N-glycosylation traits and ICD-10 diseases.

1110 Heatmap of associations between PGS for plasma N-glycosylation traits and ICD-10 1111 diseases that were statistically significant at the designated significance threshold of 1112 1.07 x 10-5. Every column represents an N-glycosylation trait, every row – an ICD-10 1113 disease. The colour of the cell represents the effects estimated in the logistic regression 1114 of the disease phenotype incidence on the PGS for each glycan trait – blue hues 1115 represent negative effects, red hues - positive, and the intensity of the colour 1116 represents the absolute value of the effect (larger values are shown in darker hues). 1117 Grey cells represent the non-significant associations. The bands under the heatmap 1118 depict the groups of N-glycosylation traits that are related to certain structural features 1119 of the N-glycans. T1D – type 1 diabetes.

1120

1121 Table 1: Twenty-five novel loci associated with total plasma N-glycosylation

1122 **discovered and replicated in this study.** Full results of discovery and replication are

1123 provided in Supplementary Table 5a, 5b. CHR:POS—chromosome and position of SNP

1124 according to GRCh37 human genome build; EA/RA—effective and reference allele;

1125 Gene—prioritized or nearest gene for a locus (Supplementary Table 6b); N—sample

- size; EAF—effective allele frequency; BETA (SE)—effect (in SD units) and standard
- 1127 error of effect; *P*—P-value; Top trait—glycan trait with the strongest association (the
- 1128 lowest *P*); Type of association—univariate or multivariate. Description of glycan traits is

1129 provided in Supplementary Table 3. Symbol \circ — the locus was previously discovered in

1130 immunoglobulin G N-glycome GWASs, as reviewed in ²⁵.

SNP info				Discovery						
SNP	CHR:POS	EA/RA	Gene	N	EAF	BETA (SE)	Р	Top trait	Type of association	
rs12726286	1:93334379	C/T	DIPKIA	7540	73.52%	0.022 (0.002)	2.24E-21	sialylation of antennary branches	multivariate	
rs1329427	1:196704559	C/T	CFH	7540	57.63%	0.016 (0.003)	5.61E-10	N-glycosylation	multivariate	
rs1260326	2:27730940	C/T	GCKR	7081	57.51%	-0.168 (0.018)	9.65E-22	G3total	univariate	
rs2470750	3:98690592	A/T	ST3GAL6	6790	59.04%	0.012 (0.002)	7.23E-10	high branching glycans	multivariate	
rs3774964	4:103519487	A/G	SLC39A8	7164	63.69%	0.109 (0.018)	1.49E-09	G0n	univariate	
rs7705720	5:95280033	C/T	ELL2 0	7540	20.03%	-0.133 (0.021)	1.32E-10	FG1S1/(FG1+FG1S1)	univariate	
rs4543384	6:139629524	C/T	TXLNB 0	6790	55.74%	0.143 (0.018)	9.67E-16	FA2BG1n	univariate	

rs7758383	6:143169723	A/G	HIVEP2 0	7540	49.87%	0.153 (0.017)	3.55E-20	FA2G2n	univariate
rs34166762	7:73018524	C/T	MLXIPL	7540	27.58%	-0.121 (0.019)	1.09E-10	A3G3S2	univariate
rs7781265	7:150950940	A/G	SMARCD3 0	7540	10.99%	0.223 (0.027)	4.75E-16	M64	univariate
rs4841133	8:9183664	A/G	LOC157273	7540	8.37%	0.013 (0.002)	6.85E-10	sialylation of antennary branches	multivariate
rs28601761	8:126500031	C/G	TRIB1	6790	57.56%	-0.143 (0.018)	7.10E-15	G3Fa/G3total	univariate
rs582118	9:136145471	A/G	ABO	7540	65.12%	0.023 (0.003)	2.00E-17	N-glycosylation	multivariate
rs174528	11:61543499	C/T	FADS2	7540	35.83%	0.013 (0.002)	1.50E-09	sialylation of antennary branches	multivariate
rs36020612	11:123344435	C/T	GRAMD1B	7319	79.96%	-0.169 (0.022)	1.66E-14	FBG2S1/ (FBG2+FBG2S1+FBG2S2)	univariate
rs11223982	11:134612702	A/G	LINC02714	6280	12.47%	0.256 (0.029)	3.45E-19	A4G4S3	univariate
rs7161378	14:65450780	C/T	MAX	7540	24.74%	-0.180 (0.019)	2.05E-20	FG3/G3total	univariate
rs28929474	14:94844947	C/T	SERPINA1	5135	97.71%	0.437 (0.072)	1.01E-09	A2G2S2	univariate
rs8046823	16:71400131	A/G	CALB2	7540	51.53%	0.021 (0.003)	1.46E-16	galactosylation of antennary branches	multivariate
rs217184	16:72105965	C/T	HP	7540	19.90%	0.211 (0.021)	5.44E-23	S3total	univariate
rs4500785	17:16848565	C/G	TNFRSF13B 0	7540	88.63%	-0.180 (0.027)	1.33E-11	FA2BG1	univariate
rs2659007	17:79217478	A/G	SLC38A10 0	7540	46.44%	0.108 (0.017)	4.07E-10	FA2BG1n	univariate
rs11669860	19:19277296	A/G	MEF2B o	7540	55.43%	-0.113 (0.017)	7.14E-11	FA2BG1n	univariate
rs2618588	20:17832658	C/T	<i>LOC107985440</i> °	7540	39.69%	0.011 (0.002)	2.02E-10	core-fucosylation	multivariate
rs2834847	21:36588180	A/C	RUNX1 0	7540	77.22%	0.160 (0.020)	2.58E-15	FBn	univariate

1133

1134

1135

Table 2: Causal associations between plasma N-glycosylation traits and ICD-10 1136 1137 diseases discovered in this study. Full results of the analysis are provided in 1138 Supplementary Tables 10a, 10b. Exposure – upstream trait in the analysis (cause); 1139 Outcome - downstream trait in the analysis; IV- instrumental variable (independent SNPs associated with upstream trait); MR - Mendelian randomization; Causal BETA 1140 1141 (SE) – causal effect of the exposure on the outcome (in log OR units of the disease unit 1142 per SD units of glycan trait if glycan trait was an exposure, or in SD units of glycan trait 1143 per log OR unit of the disease phenotype if disease phenotype was an exposure) with 1144 its standard error; P - P-value of the MR analysis.

Exposure Outcome		MR method	Number of IVs	Causal BETA (SE)	Р
PGP64 - The percentage of M6 in total neutral plasma glycans (GPn)	J45 - Asthma	Weighted median	3	0.012 (0,0036)	9.78E-04
PGP69 - The percentage of M9 in total neutral plasma glycans (GPn)	E78 - Disorders of lipoprotein metabolism and other lipidaemias	Inverse variance weighted	2	0.013 (0,0035)	1.25E-04
E78 - Disorders of lipoprotein metabolism and other lipidaemias	PGP18 - The percentage of M9	Inverse variance weighted	27	4.09 (1,1772)	5.16E-04

E78 - Disorders of lipoprotein metabolism and other lipidaemias	PGP107 - The percentage of high- mannose structures in total plasma glycans	Weighted median	27	3.01 (0,8756)	5.87E-04
--	---	-----------------	----	---------------	----------









